BioCentury
ARTICLE | Clinical News

Cytovaxine: CBX began a double-blind, dose-escalation Canadian Phase I trial in 35 healthy volunteers. Shire Pharmaceuticals Group plc (LSE:SHP, SHPGY, Basingst

April 8, 2002 7:00 AM UTC

Cytovax Biotechnologies Inc. (TSE:CBX), Edmonton, Alberta Product: Cytovaxine Business: Infectious diseases Therapeutic category: Vaccine Target: Immune cells Description: Peptide vaccine derived from...